Comparative Pharmacology
Head-to-head clinical analysis: BYOOVIZ versus MACUGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYOOVIZ versus MACUGEN.
BYOOVIZ vs MACUGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BYOOVIZ (bevacizumab-maly) is a vascular endothelial growth factor (VEGF) inhibitor that binds to VEGF-A and prevents its interaction with receptors VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
Pegaptanib is a pegylated modified oligonucleotide that binds to and inhibits vascular endothelial growth factor (VEGF-165), reducing angiogenesis and vascular permeability.
0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection once every 4 weeks (monthly). Dose adjustment is not recommended.
Intravitreal injection of 0.3 mg (0.09 mL) once every 6 weeks.
None Documented
None Documented
20 days (range 11–50 days) in patients; supports every-2- or 3-week dosing. Longer half-life in bevacizumab compared to other monoclonal antibodies due to FcRn-mediated recycling.
The terminal elimination half-life in plasma is approximately 10 days following intravitreal administration, consistent with slow clearance from the vitreous cavity and systemic absorption.
Bevacizumab (BYOOVIZ) is eliminated primarily via proteolytic catabolism, not renal or biliary excretion. No significant intact drug is excreted in urine or feces.
Pegaptanib is eliminated primarily via renal excretion, with the parent compound and metabolites excreted in urine accounting for >90% of the administered dose. Biliary/fecal elimination is negligible (<5%).
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor